Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.005
Sell
RSI(14)
43.890
Neutral
STOCH(KDJ)(9,3,3)
31.954
Neutral
ATR(14)
0.051
High Vlolatility
CCI(14)
-87.141
Neutral
Williams %R
69.231
Sell
TRIX(12,20)
-0.239
Sell
StochRSI(14)
82.855
Buy
Search
Pliant Therapeutics Inc
PLRXAdd to Watchlist
1.090USD
+0.010+0.93%
Close 07-24 16:00（ET）Quotes delayed by 15 min
67.49MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.93%
5 Days
-5.22%
1 Month
-4.39%
6 Months
-15.50%
Year to Date
-10.66%
1 Year
-30.57%
Key Figures
1.100Open
1.105High
307.55KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.50%Turnover Ratio
1.080Prev. Close
1.070Low
228.33KTurnover
LossP/E Static
0.41P/B
0.00%Div Yield TTM
-41.37%ROA
1.95052wk High
0.41Volume Ratio
-210.30MNet Profit
61.91MShares
-1.8405EPS TTM
1.21Beta
-53.62%ROE
1.09052wk Low
3.24%Amplitude
100.00%Gross Margin
67.49MMarket Cap
-1.44Reward/Risk
3.66%Risk Rate
TradingKey Stock Score of Pliant Therapeutics Inc
Currency: USD Updated: 2026-07-24Key Insights
Pliant Therapeutics Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 110 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 2.50.In the medium term, the stock price is expected to remain stable.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Pliant Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Pliant Therapeutics Inc Highlights
StrengthsRisks
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Fairly Valued
The company’s latest PE is -0.59, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.65M shares, decreasing 49.04% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 47.81K shares of this stock.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
2.500
Target Price
+131.48%
Upside Space
Pliant Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
5
analysts
Hold
Current Rating
2.500
Target Price
+131.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pliant Therapeutics Inc
PLRX
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
AbbVie Inc
ABBV
34
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.086
Buy
MA10
1.104
Sell
MA20
1.123
Sell
MA50
1.156
Sell
MA100
1.217
Sell
MA200
1.308
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Pliant Therapeutics Inc Info
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Ticker SymbolPLRX
CompanyPliant Therapeutics Inc
CEOCoulie (Bernard J)
Websitehttps://pliantrx.com/
Shareholders
Related Instruments
+0.88%
+1.60%
+0.43%
+0.90%
+0.46%
-0.72%
+1.22%
+1.25%
-1.18%
-0.12%
+0.94%
+0.90%
+1.20%
-0.02%
+2.04%
0.00%
+0.63%
-0.69%
+2.59%
+0.89%Popular Instruments
52253.700
+353.700 (+0.68%)
28485.700
+335.300 (+1.19%)
7467.700
+59.600 (+0.81%)
15028.000
+80.000 (+0.54%)
64581.000
+362.000 (+0.56%)
6314.100
+49.600 (+0.79%)
84.457
-5.586 (-6.20%)
333.020
+11.360 (+3.53%)
206.840
-1.920 (-0.92%)
4087.870
+35.520 (+0.88%)
FAQs
What is the current price of Pliant Therapeutics Inc (PLRX)?
The current price of Pliant Therapeutics Inc (PLRX) is 1.09.
What is the symbol of Pliant Therapeutics Inc?
The ticker symbol of Pliant Therapeutics Inc is PLRX.
What is the 52-week high of Pliant Therapeutics Inc?
The 52-week high of Pliant Therapeutics Inc is 1.95.
What is the 52-week low of Pliant Therapeutics Inc?
The 52-week low of Pliant Therapeutics Inc is 1.09.
What is the market capitalization of Pliant Therapeutics Inc?
The market capitalization of Pliant Therapeutics Inc is 67.49M.
Is Pliant Therapeutics Inc (PLRX) currently rated as Buy, Hold, or Sell?
According to analysts, Pliant Therapeutics Inc (PLRX) has an overall rating of signal_hold, with a price target of 2.50.
What is the Earnings Per Share (EPS TTM) of Pliant Therapeutics Inc (PLRX)?
The Earnings Per Share (EPS TTM) of Pliant Therapeutics Inc (PLRX) is -2.43.